Neuroprotective effect of the carnosine – &agr;‐lipoic acid nanomicellar complex in a model of early‐stage Parkinson's disease

[1]  J. Obeso,et al.  Compensatory mechanisms in Parkinson's disease: Circuits adaptations and role in disease modification , 2017, Experimental Neurology.

[2]  A. Inozemtsev,et al.  Carnosine prevents the development of oxidative stress under the conditions of toxic action of cadmium , 2016, Moscow University Biological Sciences Bulletin.

[3]  G. Aldini,et al.  Physiology and pathophysiology of carnosine. , 2013, Physiological reviews.

[4]  C. Perier,et al.  Neurotoxin-based models of Parkinson's disease , 2012, Neuroscience.

[5]  A. Rana.  Etiology and Pathophysiology of Parkinson's Disease , 2011 .

[6]  A. D. de Bem,et al.  The intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a new rodent model to test palliative and neuroprotective agents for Parkinson's disease. , 2011, Current pharmaceutical design.

[7]  R. Moreau,et al.  Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential. , 2009, Biochimica et biophysica acta.

[8]  S. Strack,et al.  Products of oxidative stress inhibit aldehyde oxidation and reduction pathways in dopamine catabolism yielding elevated levels of a reactive intermediate. , 2009, Chemical research in toxicology.

[9]  J. Franco,et al.  Antioxidant responses and lipid peroxidation following intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in rats: increased susceptibility of olfactory bulb. , 2007, Life sciences.

[10]  R. Prediger,et al.  The risk is in the air: Intranasal administration of MPTP to rats reproducing clinical features of Parkinson's disease , 2006, Experimental Neurology.

[11]  D. Dobrota,et al.  Carnosine Protects the Brain of Rats and Mongolian Gerbils against Ischemic Injury: After-Stroke-Effect , 2005, Neurochemical Research.

[12]  J. Sastre,et al.  Chemical intervention in senescence-accelerated mice metabolism for modeling neurodegenerative diseases: an overview , 2004 .

[13]  H. Nishino,et al.  Dopamine metabolism in the striatum of hemiparkinsonian model rats with dopaminergic grafts , 1998, Neuroscience Research.

[14]  R. Kalaria,et al.  Correlation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity with blood-brain barrier monoamine oxidase activity. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[15]  E. Junn,et al.  The role of oxidative stress in Parkinson's disease. , 2013, Journal of Parkinson's disease.